Particular interest is being shown in the development of new anti-cancer therapeutics which target KAT7/HBO1 [87] and the closely related KAT6A/B by inhibiting their HAT enzymatic activity [88] while SFPQ is speculated to be a particularly useful cancer therapy target for inactivating multiple pathways in cancer cells resistant to other chemotherapy options [89, 90]. Here, KAT6A is linked to cancer.